Page 97 - Oncology Coder News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncology coder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncology Coder Today - Breaking & Trending Today

CNN CNN News Central June 4, 2024 13:54:00

Out exactly what s going on. but what they also found was that men did not seem to account for the increase and people over the age of 50 sort of plateaued or even came down to some extent, john. that s interesting. any theories about why this is happening? yeah, i mean, there s a couple of theories. i will tell you it s a pretty significant debate within the oncology community trying to figure out what exactly is driving that. but two sort of main things came to the top. one is that we are better at screening now than even 10, 15, 20 years ago, so early onset cancers may get caught earlier because of that more advanced screening. but that doesn t seem to be all of it, john. another big component seems to be our overall health. we think about obesity. a few decades ago, obesity accounted for a smaller percentage of the overall population, but now it is close to 40% of the population, and it is a younger population that is ....

John Berman , What S Going On , Doesn T ,

Dr Jennifer Gass Provides an Overview of FCS' Next-Generation Sequencing Laboratory

Jennifer Gass, PhD, FACMG, associate director, Genetics Laboratory, Florida Cancer Specialists & Research Institute, discusses the recent Genetics Laboratory, which focuses on next-generation sequencing (NGS) testing in oncology care. ....

United States , Florida Cancer Specialists Research Institute , Florida Cancer Specialists , Research Institute , Molecular Biology ,

Early-Onset Cancer Incidence in the US Increased Through 2010s

New research demonstrated varying trends in early-onset cancer incidence based on race, sex, age, and cancer type. ....

United States , National Cancer Institute Surveillance , Cancer Institute Surveillance , End Results , Global Burden , Disease Study , Cancer Incidence , Early Onset Cancer , Breast Cancer ,

Atezolizumab monotherapy superior to chemotherapy for treatment of non-small cell lung cancer

1. Median overall survival in the atezolizumab group was 10.3 months versus 9.2 months in the chemotherapy group. 2. Patients assigned to atezolizumab had fewer treatment-related adverse events and treatment-related deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Prior first-line trials in advanced non-small-cell lung cancer (NSCLC) lacked representation for older or patients with reduced ....

Rating Level , First Line Atezolizumab , Extensive Stage Small Cell Lung , Between Sept , Lung Cancer , Non Small Cell Lung Cancer Nsclc , Chronic Disease ,

Perioperative Nivolumab and Chemotherapy in Stage III NSCLC

1. The pathological complete response rate for the experimental group was improved compared to the control group. 2. Progression-free survival and overall survival at 24 months were also improved in the experimental group with HR 0.47 and 0.43 respectively. Evidence Rating Level: 1 (Excellent) Study Rundown: The optimal treatment for non-small-cell lung cancer (NSCLC) diagnosed ....

Neoadjuvant Nivolumab , Rating Level , Overall Survival , Biomarker Analysis , Operable Stage , Small Cell Lung Cancer , Peri Operative Immunotherapy , Stage Iii Lung Cancer , Chronic Disease ,